University of Iowa Hospitals and Clinics

Clinical Research Studies

Eligibility

Gender



Age Group



More options for age range

Dates

Clinical Research started within last

Names

Principal Investigator

Showing 1 - 5 of 15 results
Page 1 of 3   

TIVA

Principal Investigator
Gary L. Pierce, PhD
Department
Department of Health and Human Physiology

Research Study to Investigate the Effects of a Common Anti-inflammatory Drug on Blood Vessel and Heart Function

Healthy, non-smoking adults age 50-79 years are invited to participate in a research study to test the effects of the drug salsalate (similar to aspirin) to test blood vessel and heart function.  Your involvement will include; blood draws, 24 hour blood pressure monitoring, surveys, and tests of blood vessel function.  Compensation will be provided.  For details, please contact Veronica Howsare (319) 467-5677 or email veronica-howsare@uiowa.edu.

 The lead investigator at the University of Iowa is Gary L. Pierce, PhD, Assistant Professor, Health Human Physiology.

age group:50 to 79 years trial start date:August 8, 2012
Gender Preference:none Trial End Date: February 20, 2015
Contact Info:

Veronica Howsare: (319) 467-5677

veronica-howsare@uiowa.edu

Keywords: Anti-Inflammatory Drug ; Blood Vessel Function ; Heart Function

Aspire

Principal Investigator
Sif Hansdottir, MD
Department
Department or Field of Study

Aspire A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso®(Treprostinil) Inhalation Solution 

Primary Outcome Measures: Describe the type and incidence of oro-/nasopharyngeal and pulmonary adverse events that may be associated with current or recent treatment with Tyvaso for PAH and with patients not treated with Tyvaso for PAH.

Please refer to www.clinicaltrials.gov for more information identifier NCT01266265

age group:1 to 99 years trial start date:April 11, 2011
Gender Preference:none Trial End Date: January 21, 2015
Contact Info:

Pulmonary Hypertension Program

Cynthia Larew RN 319-356-1028  pager # 2123

cynthia-larew@uiowa.edu

Keywords: Enter keyword ; Heart ; inhaled prostacyclin ; observational study ; PAH ; Pulmonary Arterial Hypertension ; pulmonary hypertension ; treprostinil sodium ; Tyvaso

TAH-t Post Markey Surveillance Study

Principal Investigator
Jennifer Goerbig-Campbell, MD
Department
Department or Field of Study

The purpose of this study is to demonstrate that the results achieved in the original pivotal clinical investigation of 81 subjects from five clinical sites are generalizable to new clinical sites that complete the staff training defined in the SynCardia Systems, Inc. Training Manual and who enroll subjects who meet the intended use defined in the product Instructions for Use.

 

Please refer to www.clinicaltrials.gov identifier NCT00614510 for more information.

age group:18 to 99 years trial start date:August 1, 2006
Gender Preference:none Trial End Date: January 31, 2015
Contact Info:

Cardiomyopathy Treatment Program

Page Scovel, RN

phone:  319-356-1028

fax: 319-356-7087

email: page-scovel@uiowa.edu

Keywords: Artificial heart ; cardiac disease ; Cardiomyopathy ; CHF ; Congestive heart failure ; Heart ; heart disease ; Heart failure ; Mechanical circulatory support

Ikaria

Principal Investigator
Sif Hansdottir, MD
Department
Department or Field of Study

This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).

 

Please refer to www.clinicaltrials.gov identifier NCT01457781 for further information. 

age group:18 to 80 years trial start date:April 20, 2012
Gender Preference:none Trial End Date: September 24, 2014
Contact Info:

Pulmonary Hypertension Program

Page Scovel, RN

phone:  319-356-1028

fax:  319-356-7087

email:  page-scovel@uiowa.edu

Keywords: Heart ; High blood pressure in lungs ; PAH ; PH ; Pulmonary arterial hypertension ; Pulmonary diseases ; Pulmonary hypertension

Freedom Driver Study

Principal Investigator
Jennifer Goerbig-Campbell, MD
Department
Department or Field of Study

The purposes of this study are to confirm that the Freedom Driver System is a suitable pneumatic driver for clinically stable TAH-t subjects, and that patients and lay caregivers can be trained to manage the Freedom Driver System safely outside the hospital.

 

Please refer to www.clinicaltrials.gov identifier NCT00733447 for more information.

age group:18 to 99 years trial start date:March 1, 2010
Gender Preference:none Trial End Date: November 28, 2015
Contact Info:

Cardiomyopathy Treatment Program

Page Scovel, RN

phone:  319-356-1028

fax: 319-356-7087

email:  page-scovel@uiowa.edu

Keywords: Artificial heart ; cardiac disease ; Cardiomyopathy ; CHF ; Congestive heart failure ; Heart ; heart disease ; Heart Failure ; Mechanical Circulatory Support
Page 1 of 3
« 1 2 3 » 
Results per page

Clinical Research Studies

Filters

Your Selections

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.